10x Genomics, Inc.

NASDAQ:TXG

Medical - Healthcare Information Services

Healthcare
$57.07 +7.75%

+$2.49 today

Market cap
$6.93B
Beta
2.11
P/E (TTM)
-196.0
EPS (TTM)
-$0.18
52W Low $10.48High $35.65

Volume 2.10M

Average 3.06M

TXG EBITDA Margin

EBITDA as a percentage of revenue.

10x Genomics, Inc.NASDAQ: TXG

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin holds steady near -10.7%

EBITDA Margin was -10.7% in Q3 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 6.1%, up 10.9 pp year over year. Over 3 fiscal years it widened by 25.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of -4.8% for the fiscal year ending Dec 2026, down from 0.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-10.7%-4.7 pp QoQ
Last fiscal yearDec 2025
0.6%+22.5 pp YoY
LTMSep 2026
6.1%+10.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp-48.8 pp-48.8 pp
1 year+22.5 pp-5.4 pp-28.0 pp
3 years+25.5 pp+0.6 pp-24.9 pp
5 years+12.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
0.6%
Year-over-year change
+22.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TXG compares with its peers on the latest reported figures

  • TXG's LTM Sep 2026 EBITDA Margin of 6.1% is the 7th highest of the 9 companies compared; the peer median is 26.6%.
  • Its year-over-year change of +10.9 pp is the highest of 9, against a peer median of -4.6 pp.
  • Over three fiscal years its change of +25.5 pp compares with a peer median of +20.7 pp.
TXG Competitors Peer median
EBITDA Margin for TXG and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202633.5% -1.6 pp-2.1 pp
ILMNIllumina, Inc.LTM Jun 202630.3% -11.3 pp+119.0 pp
AAgilent Technologies, Inc.LTM Jul 202627.6% +1.1 pp-1.4 pp
TECHBio-Techne CorporationLTM Sep 202626.8% +8.6 pp-11.9 pp
RVTYRevvity, Inc.LTM Jul 202626.3% -3.0 pp-8.9 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
TXG10x Genomics, Inc.LTM Sep 20266.1% +10.9 pp+25.5 pp
TWSTTwist Bioscience CorporationLTM Sep 2026-28.3% -14.5 pp+42.8 pp
LABStandard BioTools Inc.LTM Mar 2026-94.5% -30.2 pp+72.1 pp
Peer median (excluding TXG) 26.6%-4.6 pp+20.7 pp

Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue490.49M516.41M618.73M610.79M642.82M
Cost of Revenue74.09M120.39M209.41M196.3M198.94M
Gross Profit416.4M396.02M409.31M414.48M443.88M
Gross Margin84.9%76.7%66.2%67.9%69.1%
Research & Development211.75M265.67M270.33M264.7M238.63M
Selling, General & Admin257.56M298.3M343.33M344.34M316.13M
Operating Expenses469.31M563.97M674.64M609.04M554.77M
Depreciation & Amortization28.25M33.01M43.62M43.71M43.82M
EBITDA(24.6M)(128.49M)(205.11M)(133.99M)3.91M
EBITDA Margin-5.0%-24.9%-33.2%-21.9%0.6%
Operating Income(52.91M)(167.94M)(265.33M)(194.56M)(110.89M)
Operating Margin-10.8%-32.5%-42.9%-31.9%-17.2%
Interest Income206K6.65M16.91M18.45M20.05M
Interest Expense866K476K33K4K0
Other Income / Expenses(802K)5.97M16.57M16.86M70.98M
Income Before Tax(53.72M)(161.97M)(248.76M)(177.7M)(39.91M)
Pre-Tax Margin-11.0%-31.4%-40.2%-29.1%-6.2%
Income Tax Expense4.51M4.03M6.34M4.93M3.64M
Net Income(58.22M)(166M)(255.1M)(182.63M)(43.54M)
Net Margin-11.9%-32.1%-41.2%-29.9%-6.8%
EPS (Basic)(0.53)(1.46)(2.18)(1.52)(0.35)
EPS (Diluted)(0.53)(1.46)(2.18)(1.52)(0.35)
Weighted Avg Shares110.35M113.86M117.17M120.45M124.75M
Weighted Avg Shares (Diluted)110.35M113.86M117.17M120.45M124.75M

10x Genomics, Inc.

NASDAQ:TXG

Intrinsic Alpha fair value

Locked

Current Price

$57.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.